← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Soligenix, Inc.
Princeton, NJ
$56,586,355
Total funding
17
Grants
Funding over time
peak $8.7M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$55,698,552 · 15
FDA$887,803 · 2
By mechanism
N01$28,265,265 · 2
U01$14,019,189 · 2
UC1$6,433,316 · 1
R44$4,431,227 · 3
R43$2,549,555 · 7
R01$887,803 · 2
Investigators at Soligenix, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT OF RICIN VACCINE FORMULATION$8,104,724
N01 · FY2016 · AI
DEVELOPMENT OF A RECOMBINANT VACCINE FOR RICIN TOXIN$6,433,316
UC1 · FY2004 · AI
DEVELOPMENT OF RICIN VACCINE FORMULATION$5,841,498
N01 · FY2014 · AI
DEVELOPMENT OF RICIN VACCINE FORMULATION$4,599,143
N01 · FY2017 · AI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$3,333,529
U01 · FY2011 · AI
DEVELOPMENT OF RICIN VACCINE FORMULATION$2,678,720
N01 · FY2015 · AI
Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin Toxin$2,474,641
U01 · FY2006 · AI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$2,168,425
N01 · FY2015 · AI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$2,165,100
N01 · FY2014 · AI
Development of Medical Countermeasures to Mitigate or Treat GI-ARS$2,132,413
N01 · FY2013 · AI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,891,104
U01 · FY2010 · AI
Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin Toxin$1,802,850
U01 · FY2007 · AI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,341,348
U01 · FY2012 · AI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,305,761
U01 · FY2009 · AI
Development of stable and rapidly acting adjuvanted vaccines for biodefense$1,182,630
U01 · FY2013 · AI
Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP$829,746
R44 · FY2022 · AI
SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer$750,000
R44 · FY2018 · DE
Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma$750,000
R44 · FY2017 · CA
Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma$750,000
R44 · FY2018 · CA
SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer$714,817
R44 · FY2017 · DE